Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer

被引：0
|
作者：
Carla L. Alves
Sidse Ehmsen
Mikkel G. Terp
Neil Portman
Martina Tuttolomondo
Odd L. Gammelgaard
Monique F. Hundebøl
Kamila Kaminska
Lene E. Johansen
Martin Bak
Gabriella Honeth
Ana Bosch
Elgene Lim
Henrik J. Ditzel
机构：
[1] University of Southern Denmark,Department of Cancer and Inflammation Research, Institute of Molecular Medicine
[2] Institute of Clinical Research,Department of Oncology
[3] Odense University Hospital,St. Vincent’s Clinical School, Faculty of Medicine
[4] Garvan Institute of Medical Research,Division of Oncology and Pathology, Department of Clinical Sciences
[5] University of New South Wales Sydney,Department of Pathology
[6] Lund University,undefined
[7] Sydvestjysk Sygehus,undefined
[8] Academy of Geriatric Cancer Research (AgeCare),undefined
[9] Odense University Hospital,undefined
来源：
Nature Communications | / 12卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer (vol 12, 5112, 2021)
    Alves, Carla L.
    Ehmsen, Sidse
    Terp, Mikkel G.
    Portman, Neil
    Tuttolomondo, Martina
    Gammelgaard, Odd L.
    Hundebol, Monique F.
    Kaminska, Kamila
    Johansen, Lene E.
    Bak, Martin
    Honeth, Gabriella
    Bosch, Ana
    Lim, Elgene
    Ditzel, Henrik J.
    NATURE COMMUNICATIONS, 2021, 12 (01)
  • [2] Therapeutic targeting of CDK4/6 inhibitor resistant breast cancer
    Lim, Elgene
    Portman, Neil
    Alexandrou, Sarah
    Haupt, Susan
    Haupt, Ygal
    Caldon, Elizabeth
    CANCER RESEARCH, 2018, 78 (04)
  • [3] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Abeer J. Al-Qasem
    Carla L. Alves
    Sidse Ehmsen
    Martina Tuttolomondo
    Mikkel G. Terp
    Lene E. Johansen
    Henriette Vever
    Luna V. A. Hoeg
    Daniel Elias
    Martin Bak
    Henrik J. Ditzel
    npj Precision Oncology, 6
  • [4] Co-targeting CDK2 and CDK4/6 overcomes resistance to aromatase and CDK4/6 inhibitors in ER+ breast cancer
    Al-Qasem, Abeer J.
    Alves, Carla L.
    Ehmsen, Sidse
    Tuttolomondo, Martina
    Terp, Mikkel G.
    Johansen, Lene E.
    Vever, Henriette
    Hoeg, Luna V. A.
    Elias, Daniel
    Bak, Martin
    Ditzel, Henrik J.
    NPJ PRECISION ONCOLOGY, 2022, 6 (01)
  • [5] Inhibition of GPX4 enhances CDK4/6 inhibitor and endocrine therapy activity in breast cancer
    Herrera-Abreu, M. T.
    Guan, J.
    Khalid, U.
    Ning, J.
    Costa, M. R.
    Chan, J.
    Li, Q.
    Fortin, J-p.
    Wong, W. R.
    Perampalam, P.
    Biton, A.
    Sandoval, W.
    Vijay, J.
    Hafner, M.
    Cutts, R.
    Wilson, G.
    Frankum, J.
    Roumeliotis, T. I.
    Alexander, J.
    Hickman, O.
    Brough, R.
    Haider, S.
    Choudhary, J.
    Lord, C. J.
    Swain, A.
    Metcalfe, C.
    Turner, N. C.
    NATURE COMMUNICATIONS, 2024, 15 (01)
  • [6] Steatotic liver disease in metastatic breast cancer treated with endocrine therapy and CDK4/6 inhibitor
    Malon, Diego
    Molto, Consolacion
    Prasla, Shopnil
    Cuthbert, Danielle
    Pathak, Neha
    Berner-Wygoda, Yael
    Di Lorio, Massimo
    Li, Meredith
    Savill, Jacqueline
    Mittal, Abhenil
    Amir, Eitan
    Jhaveri, Kartik
    Nadler, Michelle B.
    BREAST CANCER RESEARCH AND TREATMENT, 2025, 210 (02) : 405 - 416
  • [7] Survival according to early ctDNA dynamics in advanced breast cancer (ABC) treated with endocrine therapy (ET) and a CDK4/6 inhibitor (CDK4/6i)
    Martinez Saez, O.
    Felip Falgas, E.
    Cappelletti, M.
    Tolosa, P.
    Braso-Maristany, F.
    Sanfeliu Torres, E.
    Pascual, T.
    Chic, N.
    Vidal, M.
    Adamo, B.
    Munoz, M.
    Faull, I.
    Odegaard, J.
    Patel, G.
    McEwen, R.
    Carroll, D.
    Ciruelos, E. M.
    Generali, D. G.
    Margeli Vila, M.
    Prat, A.
    ANNALS OF ONCOLOGY, 2022, 33 : S127 - S128
  • [8] Targeting CDK4/6 for Anticancer Therapy
    Qi, Jiating
    Ouyang, Zhuqing
    BIOMEDICINES, 2022, 10 (03)
  • [9] Targeting CDK4/6 in breast cancer
    Shanabag, Anusha
    Armand, Jessica
    Son, Eugene
    Yang, Hee Won
    EXPERIMENTAL AND MOLECULAR MEDICINE, 2025, 57 (02): : 312 - 322
  • [10] Targeting WEE1 Inhibits Growth of Breast Cancer Cells That Are Resistant to Endocrine Therapy and CDK4/6 Inhibitors
    Fallah, Yassi
    Demas, Diane M.
    Jin, Lu
    He, Wei
    Shajahan-Haq, Ayesha N.
    FRONTIERS IN ONCOLOGY, 2021, 11
12345